文献速递消化系统肿瘤

I-III期胰腺癌肿瘤特征、治疗分配与生存的性别差异:一项全国性研究

Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study.
PubMed 文献 · Eur J Cancer · 2024-05-14

该全国性研究基于荷兰癌症登记处2015至2020年确诊的6855例I-III期胰腺癌患者,其中51.2%为女性。校正已知混杂因素后,女性接受全身化疗的概率低于男性(OR 0.799,95%CI 0.703-0.909,p<.001),接受手术切除的概率无差异,女性总生存更差(中位OS 8.5个月 vs 9.2个月)。

要点

  • 女性I-III期胰腺癌患者接受全身化疗的概率低于男性(OR 0.799,95%CI 0.703-0.909,p<.001)。
  • 男女接受手术切除的概率无差异。
  • 女性总生存较男性更差,中位OS 8.5个月 vs 9.2个月。

核心结论

  • 该全国性研究发现,女性I-III期胰腺癌患者接受全身治疗的概率显著低于男性,且总生存较男性更差。
  • 作者认为,通过识别并解决治疗决策中可能存在的障碍或偏倚,可减少胰腺癌诊疗中的差异。

研究设计与样本

  • 从荷兰癌症登记处选取2015至2020年确诊的I-III期胰腺癌患者,共6855例,其中51.2%为女性。
  • 采用多变量logistic回归分析性别与接受手术和/或全身治疗概率的关联,校正年龄、体能状态、合并症、肿瘤位置、肿瘤分期和既往恶性肿瘤。
  • 采用log rank检验和多变量Cox比例风险分析评估总生存。

主要发现

  • 校正已知混杂因素后,女性接受全身化疗的概率低于男性(OR 0.799,95%CI 0.703-0.909,p<.001)。
  • 男女接受手术切除的概率无差异。
  • 女性总生存较男性更差,中位OS分别为8.5个月和9.2个月(95%CI 8.669-9.731)。

临床怎么用

  • 作者认为,通过识别并解决治疗决策中可能存在的障碍或偏倚,可减少胰腺癌诊疗中的差异。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sex and gender are modulators of health and disease and may have impact on treatment allocation and survival in patients with cancer. In this study, we analyzed the impact of sex and gender on treatment allocation and overall survival in patients with stage I-III pancreatic cancer. METHODS: Patients with stage I-III pancreatic cancer diagnosed between 2015 and 2020 were selected from the nationwide Netherlands Cancer Registry. Associations between sex and gender and the probability of receiving surgical and/or systemic treatment were examined with multivariable logistic regression analyses. Overall survival was assessed with log rank test and multivariable Cox proportional hazard analysis. RESULTS: Among 6855 patients, 51.2 % were female. Multivariable logistic regression analyses with adjustment for known confounders (age, performance status, comorbidities, tumor location, tumor stage and previous malignancies) showed that females less often received systemic chemotherapy compared to males (OR 0.799, 95 %CI 0.703-0.909, p < .001). No difference was found in the probability for undergoing surgical resection. Furthermore, females had worse overall survival compared to males (median OS 8.5 and 9.2 months respectively, 95 %CI 8.669-9.731). CONCLUSION: This nationwide study found that female patients with stage I-III pancreatic cancer significantly less often received systemic treatment and had worse overall survival as compared to males. Disparities in pancreatic cancer care can be decreased by recognizing and resolving potential obstacles or biases in treatment decision-making.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gehrels AM, Wagner AD, Besselink MG, et al. Gender differences in tumor characteristics, treatment allocation and survival in stage I-III pancreatic cancer: a nationwide study. Eur J Cancer. 2024. PMID: 38781719. doi:10.1016/j.ejca.2024.114117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。